Back to search

Virginia Commonwealth University

Sildenafil and celecoxib interact to kill breast cancer cells

Abstract

dc:description.abstract

Breast cancer is the second most commonly diagnosed cancer among American women and is responsible for the second highest number of cancer-related deaths. Targeted therapeutic agents sildenafil, a phosphodiesterase type 5 inhibitor, and celecoxib, a cyclooxygenase-2 inhibitor, have been used individually in conjunction with other chemotherapeutic agents to enhance cell killing in a variety of cancers. Sildenafil when combined with traditional chemotherapeutic drugs, such as the taxanes and anthracyclines, or celecoxib combined with traditional hormone therapies have been used to increase cytotoxicity and cell killing. The data presented here demonstrates that the novel combination of sildenafil and celecoxib work together to enhance cell killing in both receptor positive and triple negative breast cancer through the induction of autophagy, ER stress, as well as both intrinsic and extrinsic apoptosis.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Biochemistry

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Binion, Brittany
Contributors dc:contributor
  • Dr. Paul Dent
  • Dr. Laurence Booth
  • Dr. Devanand Sarkar

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • © The Author

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Binion, Brittany. Sildenafil and celecoxib interact to kill breast cancer cells. Thesis thesis, https://doi.org/10.25772/TGYV-XE12